Prot #TL-895-203: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)

Altman, Jessica K (PD/PI)

Medicine, Hematology Oncology Division

Project: Research project

Status	Finished
Effective start/end date	5/4/21 → 5/4/24

Funding

PSI Pharma Support America Inc. ((OE) Prot #TL-895-203 // (OE) Prot #TL-895-203)
Telios Pharma, Inc. ((OE) Prot #TL-895-203 // (OE) Prot #TL-895-203)